ranibizumab

all catalysts(0)

nothing on the calendar yet

News(6)

• Kodiak skyrockets on positive study data for 2 eye drugs
  The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
  biopharma_dive · 1d ago
• Merck reveals study success, and possible safety worries, for eye drug hopeful
  A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.
  biopharma_dive · 5d ago
• Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
  Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
  biospace · 5d ago
• Merck sees pivotal victory for $3B eye disease prospect
  Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion take…
  fiercebiotech · 6d ago
• EyePoint plummets on pivotal data for main drug
  Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.
  biopharma_dive · 1mo ago
• Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
  This webinar provides an assessment of recent job market activity across biopharma and explores how companies approaching commercial readiness or building out sales and marketing teams can navigate…
  biospace · 2mo ago